Mutant KRAS is a druggable target for pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages 20723-20728

  Khvalevsky, Elina Zorde ^a   Gabai, Racheli ^a   Rachmut, Itzhak Haim ^a   Horwitz, Elad ^a   Brunschwig, Zivia ^a   Orbach, Ariel ^a   Shemi, Adva ^a   Golan, Talia ^b   Domb, Abraham J ^c   Yavin, Eylon ^c   Giladi, Hilla ^a   Rivkin, Ludmila ^a   Simerzin, Alina ^a   Eliakim, Rami ^d   Khalaileh, Abed ^a   Hubert, Ayala ^a   Lahav, Maor ^d   Kopelman, Yael ^a   Goldin, Eran ^a   Dancour, Alan ^a   Hants, Yael ^a   Arbel Alon, Sagit ^e   Abramovitch, Rinat ^a   Shemi, Amotz ^a   Galun, Eithan ^a   more..

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Gene therapy; Targeted therapy

Indexed keywords

K RAS PROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA INTERFERENCE; TUMOR GROWTH;

EID: 84890824325     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314307110     Document Type: Article

References (23)

1. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605-1617.
2. Karamitopoulou E (2012) Tumor budding cells, cancer stem cells and epithelial-Mesenchymal transition-Type cells in pancreatic cancer. Front Oncol 2:209.
3. Delpu Y, et al. (2011) Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics 12(1):15-24.
4. Jones S, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801-1806.
5. Belda-Iniesta C, et al. (2008) Molecular biology of pancreatic cancer. Clin Transl Oncol 10(9):530-537.
6. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3:157-188.
7. Feldmann G, Beaty R, Hruban RH, Maitra A (2007) Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 14(3):224-232.
8. Quinlan MP, Quatela SE, Philips MR, Settleman J (2008) Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol 28(8):2659-2674.
9. Sun C, et al. (2001) Characterization of the mutations of the K-Ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 8(1):89-92.
10. Villanueva A, et al. (1996) Diagnostic utility of K-Ras mutations in fine-Needle aspirates of pancreatic masses. Gastroenterology 110(5):1587-1594.
11. Singh A, et al. (2009) A gene expression signature associated with K-Ras addiction reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489-500.
12. Réjiba S, Wack S, Aprahamian M, Hajri A (2007) K-Ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 98(7):1128-1136.
13. Leucuta SE (2012) Drug delivery systems with modified release for systemic and biophase bioavailability. Curr Clin Pharmacol 7(4):282-317.
14. Mohtaram NK, Montgomery A, Willerth SM (2013) Biomaterial-Based drug delivery systems for the controlled release of neurotrophic factors. Biomed Mater 8(2): 022001.
15. Hudson D, Margaritis A (2013) Biopolymer nanoparticle production for controlled release of biopharmaceuticals. Crit Rev Biotechnol, 10.3109/07388551.2012.743503.
16. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA (2005) Molecular consequences of silencing mutant K-Ras in pancreatic cancer cells: Justification for K-Ras-Directed therapy. Mol Cancer Res 3(7):413-423.
17. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329-333.
18. Kramer N, et al. (2013) In vitro cell migration and invasion assays. Mutat Res 752(1):10-24.
19. Klopstock N, Levy C, Olam D, Galun E, Goldenberg D (2007) Testing transgenic regulatory elements through live mouse imaging. FEBS Lett 581(21):3986-3990.
20. Sharma SV, Settleman J (2007) Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 21(24):3214-3231.
21. Friday BB, Adjei AA (2005) K-Ras as a target for cancer therapy. Biochim Biophys Acta 1756(2):127-144.
22. Zimmermann G, et al. (2013) Small molecule inhibition of the KRAS-PDEä interaction impairs oncogenic KRAS signalling. Nature 497(7451):638-642.
23. Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.